Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PSA: an update.

Claude Schulman1

  • 1Department of Urology, University Clinics of Brussels, Erasme Hospital, Belgium. claude.Schulman@ulb.ac.be

Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Societa Italiana Di Ecografia Urologica E Nefrologica
|February 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alternating Cystoscopy with Bladder EpiCheck<sup>®</sup> in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model.

Bladder cancer (Amsterdam, Netherlands)·2024
Same author

Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results.

Minerva urology and nephrology·2023
Same author

3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction.

Prostate cancer and prostatic diseases·2020
Same author

Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study.

World journal of urology·2020
Same author

Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up.

BJU international·2018
Same author

Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.

The Journal of urology·2017
Same journal

Flat magnetic stimulation treatment for urinary incontinence: analysis and six months follow-up of 180 cases.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica·2026
Same journal

Management of complex pelvic fracture urethral injury following high-energy trauma in female patients: a case series.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica·2026
Same journal

Renal suppurative infections: analysis of a series of 32 cases.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica·2026
Same journal

Safety and efficacy of navigable suction-assisted ureteral access sheath for treatment of kidney stones.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica·2026
Same journal

Diagnostic performance of PI-RADS and PSA density for detecting clinically significant prostate cancer.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica·2026
Same journal

The relationship of prostate cancer diagnosed by magnetic resonance imaging/transrectal ultrasound prostate fusion biopsy with standard and adjusted anogenital distances.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica·2026
See all related articles

Prostate-Specific Antigen (PSA) levels alone cannot rule out prostate cancer. Risk assessment requires considering age, Gleason score, and PSA velocity for personalized treatment decisions.

Area of Science:

  • Urology
  • Oncology
  • Medical Diagnostics

Background:

  • Prostate-Specific Antigen (PSA) is a biomarker for prostate cancer, but its specificity is limited.
  • A definitive PSA cutoff value to exclude prostate cancer does not exist.
  • PSA levels can be influenced by age and benign prostatic hyperplasia (BPH).

Purpose of the Study:

  • To evaluate the role of PSA in prostate cancer risk assessment.
  • To identify key criteria for differentiating patients at high risk of dying from prostate cancer.
  • To guide conservative management for low-risk patients and early intervention for high-risk individuals.

Main Methods:

  • Analysis of PSA levels in relation to age, transition zone size (BPH), and Gleason score.
  • Consideration of PSA velocity as a predictive factor.

Related Experiment Videos

  • Review of established reference data, including Oesterling's 1996 JAMA publication on age-dependent PSA.

    • Main Results:

    • PSA is not a standalone diagnostic tool; elevated levels do not definitively indicate cancer or its severity.
    • Age and Gleason score (patterns 4 or 5) are critical factors in risk stratification.
    • PSA velocity is an important metric for assessing disease progression and risk.

    Conclusions:

    • Prostate cancer risk assessment necessitates a multifactorial approach beyond PSA alone.
    • Early and aggressive treatment is recommended for high-risk patients (younger age, high Gleason, significant PSA velocity).
    • A conservative approach is advised for patients with a low risk of mortality from prostate cancer.